{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:34:50Z","timestamp":1740155690659,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/nrneph.2014.138","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T08:11:00Z","timestamp":1407226260000},"page":"489-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progression of polycystic kidney disease\u2014a lack of progress?"],"prefix":"10.1038","volume":"10","author":[{"given":"Stephen","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopala","family":"Rangan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"BFnrneph2014138_CR1","doi-asserted-by":"publisher","unstructured":"Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. http:\/\/dx.doi.org\/10.1038\/ki.2014.120 .","DOI":"10.1038\/ki.2014.120"},{"key":"BFnrneph2014138_CR2","doi-asserted-by":"publisher","unstructured":"Shaw, C., Simms, R. J., Pitcher, D. & Sandford, R. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfu087 .","DOI":"10.1093\/ndt\/gfu087"},{"key":"BFnrneph2014138_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1440-1797.2004.00259.x","volume":"9","author":"JH Stewart","year":"2004","unstructured":"Stewart, J. H., McCredie, M. R., Williams, S. M. & McDonald, S. P. Interpreting incidence trends for treated end-stage renal disease: Implications for evaluating disease control in Australia. Nephrology 9, 238\u2013246 (2004).","journal-title":"Nephrology"},{"key":"BFnrneph2014138_CR4","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","volume":"5","author":"S Klahr","year":"1995","unstructured":"Klahr, S. et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 5, 2037\u20132047 (1995).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2014138_CR5","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014138_CR6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","volume":"57","author":"C Patch","year":"2011","unstructured":"Patch, C., Charlton, J., Roderick, P. J. & Gulliford, M. C. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am. J. Kid. Dis. 57, 856\u2013862 (2011).","journal-title":"Am. J. Kid. Dis."},{"key":"BFnrneph2014138_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1681\/ASN.2007101100","volume":"19","author":"JJ Grantham","year":"2008","unstructured":"Grantham, J. J. Therapy for polycystic kidney disease? It's water, stupid! J. Am. Soc. Nephrol. 19, 1\u20137 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2014138_CR8","doi-asserted-by":"publisher","unstructured":"Higashihara, E. et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfu093 .","DOI":"10.1093\/ndt\/gfu093"},{"key":"BFnrneph2014138_CR9","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","volume":"28","author":"HP Neumann","year":"2013","unstructured":"Neumann, H. P. et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol. Dial. Transplant. 28, 1472\u20131487 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2014138_CR10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/ndt\/gfr467","volume":"27","author":"B Orskov","year":"2012","unstructured":"Orskov, B., Sorensen, V. R., Feldt-Rasmussen, B. & Strandgaard, S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol. Dial. Transplant. 27, 1607\u20131613 (2012).","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:43:38Z","timestamp":1684471418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2014.138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFnrneph2014138"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2014.138","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"assertion":[{"value":"5 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. and G.R. are site-investigators in an ongoing clinical trial of tolvaptan for ADPKD (Otsuka Pharmaceutical Ltd)","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}